William Blair Issues Pessimistic Forecast for TLX Earnings

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) – Equities research analysts at William Blair cut their FY2026 earnings per share (EPS) estimates for Telix Pharmaceuticals Limited American Depositary Shares in a research report issued to clients and investors on Monday, April 28th. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $1.03 for the year, down from their previous estimate of $1.05. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares’ current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals Limited American Depositary Shares’ FY2027 earnings at $1.40 EPS.

Separately, UBS Group raised their price target on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Price Performance

Shares of NASDAQ TLX opened at $17.40 on Tuesday. The business has a 50-day simple moving average of $17.24. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $13.61 and a fifty-two week high of $30.36.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.